ENTITY
Biogen Inc

Biogen Inc (BIIB US)

132
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
bullishBiogen Inc
07 May 2025 15:39Issuer-paid

Biogen, Inc. - Steady as She Goes as the Ship Continues to Turn Slowly

Despite beating expectations with a 6% Y/Y growth in reported revenues to $2.4B (8% Y/Y growth on a constant currency basis) for 1Q25

Logo
301 Views
Share
bullishBiogen Inc
31 Mar 2025 17:22Issuer-paid

Biogen, Inc: Breakthrough Drug Developer in Reset Mode; Initiating Coverage

Biogen built its reputation on a differentiated modality-agnostic approach to drug development, deploying innovative technologies to address...

Logo
258 Views
Share
14 Jan 2025 13:34Issuer-paid

Biopharma Week in Review - January 13, 2025

As investors prepped for company updates and significant news flow, signs of M&A activity were trickling in, with BIIB bidding for SAGE, LLY...

Logo
190 Views
Share
14 Oct 2024 15:58Issuer-paid

Biopharma Week in Review - October 14, 2024

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A. Last week, SRRK gained from...

Logo
313 Views
Share
29 Jul 2024 23:15Issuer-paid

Biopharma Week in Review - Jul 29, 2024

Last week, IONS matched Ultragenyx’s Angelman benefit, with maybe better safety. PFE and SGMO had approvable gene therapy results in hemophilia A,...

Logo
219 Views
Share
x